Regeneron's licensing agreement with Bristol-Myers Squibb and Ono Pharmaceutical for its cancer drug Libtayo has a new royalty structure, significantly lowering its royalty burden. This change directly impacts the product's profitability and cost of goods sold.
Filing excerpt
Under the agreement, we paid royalties of 8.0% on worldwide sales of Libtayo through December 31, 2023, and are obligated to pay royalties of 2.5% from January 1, 2024 through December 31, 2026.
What this signalsFilings often name leadership changes, deals and spending plans.
Vendors
Vendors named
sec-10kjointVentureGet every 10-K signal for Regeneron and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Regeneron this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/50d11a58-786c-40e6-8061-af6b164684d7 returns this record as JSON. POST /v1/companies/enrich returns every signal for regeneron.com.
{
"signal_id": "50d11a58-786c-40e6-8061-af6b164684d7",
"signal_type": "sec-10k",
"signal_subtype": "jointVenture",
"detected_at": "2026-02-10T07:49:34.287+00:00",
"company": {
"name": "Regeneron",
"domain": "regeneron.com"
},
"data": {
"detail": "Regeneron's licensing agreement with Bristol-Myers Squibb and Ono Pharmaceutical for its cancer drug Libtayo has a new royalty structure, significantly lowering its royalty burden. This change directly impacts the product's profitability and cost of goods sold.",
"metrics": {
"pct": 0.08,
"timeframe": "multi_year",
"pct_context": "royalties on worldwide sales of Libtayo through December 31, 2023"
},
"summary": "Libtayo royalty rate paid to Bristol-Myers Squibb drops from 8% to 2.5% as of Jan 2024.",
"excerpts": "Under the agreement, we paid royalties of 8.0% on worldwide sales of Libtayo through December 31, 2023, and are obligated to pay royalties of 2.5% from January 1, 2024 through December 31, 2026.",
"relevance": 0.7,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm",
"filing_date": "2026-02-04",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "New entity needs",
"signal_category": "strategic",
"vendors_mentioned": [
"Bristol-Myers Squibb",
"E. R. Squibb & Sons, L.L.C.",
"Ono Pharmaceutical Co., Ltd."
]
}
}
curl https://signals.autobound.ai/v1/signals/50d11a58-786c-40e6-8061-af6b164684d7 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"regeneron.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.